Deferasirox Tablet, For Suspension
Product Images NDC 45963-455

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Deferasirox (NDC 45963-455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

9c6b4e1d-figure-01 (Image 1)

FDA Label Image

250 (Image 10)

Deferasirox Tablets for oral suspension are dispensed in a container with 30 tablets. The pharmacist should accompany each patient with a medication guide. The dosage must be indicated in the package insert. The tablets must be dispersed in water and cannot be chewed or swallowed whole. A tight, light-resistant container must be dispensed to store the tablets at a controlled temperature between 15-30°C. The medicine is manufactured by Teva Pharmaceuticals and the lot number is 45963-455-30. The text also includes a serial coding area. Print Medication Guides are available on the tevausa.com/medguides website.*

FDA Label Image

500 (Image 11)

This is a description of a medication named Deferasirox Tablets that come in a bottle of 30 tablets with 500mg of the active ingredient. It provides instructions to disperse the tablets in water before ingestion, rather than swallowing or chewing them whole. The medication guide should be provided to patients by a pharmacist. The tablets should be kept in a light-resistant container at a temperature of 25°C (77°F) and protected from moisture. The medication should be kept out of reach of children. The medication is manufactured by Teua Pharmaceuticals in Parsippany, NJ. The code NDC 45963-456-30 identifies this medication product.*

FDA Label Image

9c6b4e1d-figure-02 (Image 2)

FDA Label Image

9c6b4e1d-figure-03 (Image 3)

FDA Label Image

9c6b4e1d-figure-04 (Image 4)

FDA Label Image

9c6b4e1d-figure-05 (Image 5)

This data appears to be related to the study of liver iron content and serum ferritin levels. The text includes information on dosages of Deferasirox Tablets, which seems to be a medication for iron-overload conditions such as hereditary hemochromatosis. The has also captured some numerical figures indicating the change in serum ferritin and liver iron content (in mg Felg dw). However, the meaning behind the first two lines of text is not clear.*

FDA Label Image

9c6b4e1d-figure-06 (Image 6)

FDA Label Image

9c6b4e1d-figure-07 (Image 7)

FDA Label Image

9c6b4e1d-figure-08 (Image 8)

FDA Label Image

125 (Image 9)

Deferasirox Tablets for Oral Suspension used to remove excess iron from the body. It is a prescription-only medication containing 30 tablets, each tablet contains Deferasirox 125mg. The pharmacist must dispense the medication guide to every patient. The tablets should be dispersed in water or apple juice before ingestion to consume them. The medication should be kept in a light-resistant container within the temperature range from 15 to 30°C. Teua Pharmaceuticals manufactures the medication. The lot number and expiration date are indicated on the packaging. Serialization Coding Area in also provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.